Among the next generation of highly specific FLT3 TKIs that have been developed, quizartinib (AC220) compares favorably in monotherapy to standard treatment in refractory or relapsed AML (QuANTUM-R trial (NCT02039726)5), and is currently being evaluated in first line treatment in combination with chemotherapy (QuANTUM-First trial (NCT02668653)). Here, FLT3 is linked to acute myeloid leukemia.